| Paclitaxel | Head and neck cancer, in all type of patients | vs PF | complete response to study treatment by 75% suggested complete response to induction CT by 147% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| death (overall survival) | 0.85 [0.57 1.28] | p=1.00 | 0 | 382 | 1 | Hitt paclitaxel, | | disease free survival | no data | | progression or death (progression free survival PFS) | NaN [NaN NaN] | p=1.00 | 0 | 382 | 1 | Hitt paclitaxel, | | death or laryngectomy | no data | | laryngectomy | no data | | larynx preservation | no data | | complete response to study treatment | 1.75 [1.15 2.66] | p=0.04 | 0 | 382 | 1 | Hitt paclitaxel, | | complete response to induction CT | 2.47 [1.48 4.13] | p=0.04 | 0 | 382 | 1 | Hitt paclitaxel, | | treatment failure | no data | | treatment related death | no data | | death of unknown cause | no data | | cancer related death | no data | | Toxic death during induction CT | 0.51 [0.09 2.82] | p=1.00 | 0 | 382 | 1 | Hitt paclitaxel, | | All grade 3 to 4 events during induction CT | 1.63 [0.52 5.09] | p=1.00 | 0 | 382 | 1 | Hitt paclitaxel, | | neutropenia (grade 3-4) during induction CT | 1.05 [0.63 1.75] | p=1.00 | 0 | 382 | 1 | Hitt paclitaxel, |
| Trial | Studied treatment | Control | Patients |
|---|
| Hitt paclitaxel, 2005 | induction chemotherapy with paclitaxel, cisplatin, and fluorouracil | induction chemotherapy with cisplatin and FU | locally advanced head and neck cancer |
| |
